BiomX announces $3M private placement

3 days ago 8

TipRanks

Tue, December 30, 2025 astatine 7:15 AM CST 1 min read

BiomX (PHGE) entered into definitive agreements successful transportation with a backstage concern successful nationalist equity financing for expected gross proceeds of astir $3M, earlier deducting placement cause fees and different offering expenses. H.C. Wainwright & Co. acted arsenic the exclusive placement cause for the backstage placement. In the Private Placement, the Company agreed to contented and merchantability shares of its Series Y Convertible Preferred Stock, with a stated worth of $1,000 per share, unneurotic with warrants with an aggregate stated worth of up to $3.3M, for an aggregate acquisition terms of $3M. Each stock of Series Y Convertible Preferred Stock volition accrue dividends astatine a complaint of 15% per annum, payable quarterly, and volition person a maturity of 1 twelvemonth from the closing date. The Series Y Convertible Preferred Stock volition beryllium convertible into shares of the Company’s communal stock, taxable to the limitations acceptable distant successful the definitive agreements, including the receipt of stockholder support to the grade required nether NYSE American rules. In transportation with the Private Placement, the Company volition besides contented warrants to get up to 3,300,000 shares of the Company’s communal stock. The warrants volition person a five-year word and an workout terms initially adjacent to $2.00, the applicable conversion terms of the Series Y Convertible Preferred Stock, taxable to definite adjustments if stockholder support is obtained. The Private Placement is expected to adjacent connected oregon astir December 30, taxable to the restitution of customary closing conditions.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected PHGE:

Disclaimer & DisclosureReport an Issue

BiomX Discontinues Study and Files for Insolvency
BiomX Discontinues Phase 2b Trial for BX004
BiomX discontinues Phase 2b BX004 trial, plans cost-cutting measures
BiomX Updates connected Phase 2b Study for BX004
BiomX provides update connected BX004 Phase 2b proceedings successful Cystic Fibrosis

Read Entire Article